Symptom Advice .com » thomson http://symptomadvice.com Tue, 29 May 2012 22:17:13 +0000 en hourly 1 http://wordpress.org/?v=3.0.1 Page Not Found http://symptomadvice.com/page-not-found/ http://symptomadvice.com/page-not-found/#comments Wed, 03 Aug 2011 05:34:09 +0000 Symptom Advice http://symptomadvice.com/page-not-found/

Thomson Reuters is the world’s largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

]]> http://symptomadvice.com/page-not-found/feed/ 0 Novartis gains positive CHMP opinion for Gilenya®, first oral multiple sclerosis treatment recommended for approval in the European Union http://symptomadvice.com/novartis-gains-positive-chmp-opinion-for-gilenya%c2%ae-first-oral-multiple-sclerosis-treatment-recommended-for-approval-in-the-european-union/ http://symptomadvice.com/novartis-gains-positive-chmp-opinion-for-gilenya%c2%ae-first-oral-multiple-sclerosis-treatment-recommended-for-approval-in-the-european-union/#comments Thu, 03 Feb 2011 04:51:09 +0000 Symptom Advice http://symptomadvice.com/novartis-gains-positive-chmp-opinion-for-gilenya%c2%ae-first-oral-multiple-sclerosis-treatment-recommended-for-approval-in-the-european-union/

Novartis International AG /Novartis gains positive CHMP opinion for Gilenya®, first oral multiple sclerosis treatment recommended for approval in the European Union Processed and transmitted by Thomson Reuters.the issuer is solely responsible for the content of this announcement.

* Gilenya recommended in the EU for people with highly active relapsing- remitting MS despite treatment with beta interferon, or in patients with rapidly evolving severe relapsing-remitting MS

* Gilenya showed superior efficacy to interferon beta-1a IM, a commonly prescribed treatment, reducing relapses by 52% (p

]]> http://symptomadvice.com/novartis-gains-positive-chmp-opinion-for-gilenya%c2%ae-first-oral-multiple-sclerosis-treatment-recommended-for-approval-in-the-european-union/feed/ 0